Plasma clusterin was increased in overweight and obese individuals, correlated with BMI, and was suggested as a surrogate obesity marker [29]; properdin levels and indicators of complement activation were increased in donors with a family history of T2D and suggested as markers of future risk [30, 31]. Here, CLU is linked to obesity disorder.